{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:43:11Z","timestamp":1782142991846,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jacl.2018.01.004","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T02:59:11Z","timestamp":1515725951000},"page":"277-291.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term efficacy and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials"],"prefix":"10.1016","volume":"12","author":[{"given":"Jie","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-lin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jacl.2018.01.004_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"25 Pt B","key":"10.1016\/j.jacl.2018.01.004_bib2","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.01.004_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2018.01.004_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacl.2018.01.004_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/13543784.2013.822485","article-title":"Current phase II proprotein convertase subtilisin\/kexin 9 inhibitor therapies for dyslipidemia","volume":"22","author":"Lee","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"18","key":"10.1016\/j.jacl.2018.01.004_bib8","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jacl.2018.01.004_bib9","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2018.01.004_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.01.004_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.jacl.2018.01.004_bib12","doi-asserted-by":"crossref","first-page":"e001937","DOI":"10.1161\/JAHA.115.001937","article-title":"Efficiency and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials","volume":"4","author":"Li","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jacl.2018.01.004_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"43","key":"10.1016\/j.jacl.2018.01.004_bib15","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacl.2018.01.004_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.jacl.2018.01.004_bib17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2018.01.004_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.01.004_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A phase III randomized trial evaluating alirocumab 300mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.jacl.2018.01.004_bib20","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY JAPAN randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"issue":"5","key":"10.1016\/j.jacl.2018.01.004_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dL or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"16","key":"10.1016\/j.jacl.2018.01.004_bib22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2018.01.004_bib23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jacl.2018.01.004_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular sisease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacl.2018.01.004_bib25","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2018.01.004_bib26","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacl.2018.01.004_bib28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacl.2018.01.004_bib29","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jacl.2018.01.004_bib30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","article-title":"Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects","volume":"234","author":"B\u00e9liard","year":"2014","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2018.01.004_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 Forum. PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2018.01.004_bib32","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacl.2018.01.004_bib33","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jacl.2018.01.004_bib34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2018.01.004_bib35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the National Lipid Association","volume":"11","author":"Orringer","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"25","key":"10.1016\/j.jacl.2018.01.004_bib36","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"9753","key":"10.1016\/j.jacl.2018.01.004_bib37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacl.2018.01.004_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bcp.13202","article-title":"Statins and mortality: the untold story","volume":"83","author":"Kostapanos","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jacl.2018.01.004_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bcp.12945","article-title":"Cholesterol trials and mortality","volume":"82","author":"Warren","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.jacl.2018.01.004_bib40","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.jacl.2018.01.004_bib41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2018.01.004_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"39","key":"10.1016\/j.jacl.2018.01.004_bib43","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2018.01.004_bib44","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2018.01.004_bib45","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2018.01.004_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-017-0619-0","article-title":"Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease","volume":"112","author":"Glerup","year":"2017","journal-title":"Basic Res Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418300242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418300242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T08:29:10Z","timestamp":1570609750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418300242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1933287418300242"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.01.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}